AOTI’s Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading Worldwide Wound Care Conferences
It is clear there is a growing tsunami of interest in our products and their unprecedented complete healing benefits. We expect and hope that as our latest state-of-the-art Randomized Controlled Trial (RCT) is published that TWO2therapy will be made available to all chronic wound patients worldwide.
AOTI Enters Into Multi-Million USD Strategic Relationship for Chinese Market
OCEANSIDE, Calif., Jan. 18, 2019 /PRNewswire/ — AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen...
AOTI to Participate at Jefferies 2018 London Healthcare Conference and Present at the 3rd Annual INV€$TIVAL Showcase in Partnership with Jefferies
OCEANSIDE, Calif., Oct. 18, 2018 /PRNewswire/ — AOTI Inc. announced today that it will participate at Jefferies 2018 London Healthcare Conference, being held on November 14 and 15, 2018 in London, United Kingdom. Now in its ninth year, the Jefferies conference...
TWO2 Randomized Controlled Trial Chosen as One of the Best Abstracts Presented at the Leading Diabetic Foot Global Conference
OCEANSIDE, Calif., Oct. 11, 2018 /PRNewswire/ — AOTI Inc. announced today that expanded results from its recently concluded Randomized Controlled Trial (RCT) demonstrating the efficacy of its patented multi-modality Topical Wound Oxygen (TWO2) homecare therapy...
Opening of New Manufacturing Facility to Meet Expanding Demand for Topical Wound Oxygen (TWO2) Therapy Devices
We are delighted to invest in this new facility that will allow us to more effectively ramp up production of our unique multi-modality wound care therapy product line to meet our continually expanding supply needs,” stated Dr. Mike Griffiths, Chief Executive Officer and President of AOTI.